Fig. 3
Effects of lurbinectedin, ecubectedin and PM54 on cGAS/STING pathway activation and downstream cytokines in MPM cells. (A) Representative immunoblot images of the indicated proteins belonging to the cGAS/STING pathway, in MPM#1 (epithelioid, BAP1 positive: Epi, BAP+) and MPM#7 (sarcomatoid, BAP1 negative: Sar, BAP−), treated or not (-) with cisplatin + pemetrexed (Pt + PMX), lurbinectedin (L), ecubectedin and PM54 at their IC50 for 24 h, actin was used as a loading control. The figure is representative of 1 out of 3 experiments. (B) Activation of NF-kB after the treatment indicated in (A). Data are expressed as means ± SD of 12 MPM samples (n = 3 independent experiments, in duplicates). **p < 0.01, ***p < 0.001: vs. untreated cells; °°°p < 0.001: vs. Pt + PMX. (C) Pro-inflammatory cytokine/chemokine levels released in the supernatant of MPM cell cultures after the treatments indicated in (A). Data are expressed as means ± SD of 12 MPM samples (n = 3 independent experiments, in duplicates). *p < 0.05, ***p < 0.001: vs. untreated cells; °°°p < 0.001: vs. Pt + PMX